Fig. 4
From: A functional role of LEFTY during progesterone therapy for endometrial carcinoma
Changes in LEFTY expression during progesterone therapy for Em Cas. a Staining by hematoxylin and eosin (HE) and IHC for the indicated molecules in good (upper) and poor (lower) response cases after progesterone (MPA) treatment. Insets show the magnified views of the boxed areas in upper panels, while the focal carcinomatous areas with a weak response to the therapy are indicated by arrows in lower panels. Original magnification, ×100 and ×400 (inset). b IHC scores for LEFTY and pSmad2 (left) and Ki-67 LIs (right) in Em Ca cases before and after progesterone therapy (MPA Tx) for 3, 6, and 9 months (m). c IHC scores for LEFTY and pSmad2 (left) and Ki-67 LIs (right) in Em Ca cases before progesterone therapy and in therapeutic efficacy (TE) 0–2 and 3–4 groups. d Left and middle: staining by HE, IHC for LEFTY, and ISH for LEFTY1 and LEFTY2 mRNAs in Em Ca tissues before (left) and after MPA therapy (middle) in a good response case. Insets show the magnified views of the boxed areas. Original magnification, ×200 and ×400 (inset). Right: ISH score for LEFTY1 and LEFTY2 mRNAs in Em Ca cases before and after progesterone therapy for 3 months (m)